These authors contributed equally to this work.
The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin†
Article first published online: 22 JAN 2014
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 53, Issue 7, pages 1963–1967, February 10, 2014
How to Cite
Pathak, R. K., Marrache, S., Choi, J. H., Berding, T. B. and Dhar, S. (2014), The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin. Angew. Chem. Int. Ed., 53: 1963–1967. doi: 10.1002/anie.201308899
We thank Samuel Kennedy for his initial efforts in synthesizing Platin-A, and Kasey Darley for coming up with the name Platin-A. We thank Dr. Ramaraja Ramasamy for potentiostat measurements and Dr. Todd C. Harrop for IR measurements. This work was supported by a Department of Defense Prostate Cancer Idea award (W81XWH-12-1-0406) to S.D.
- Issue published online: 6 FEB 2014
- Article first published online: 22 JAN 2014
- Manuscript Received: 12 OCT 2013
- Department of Defense Prostate Cancer Idea award. Grant Number: W81XWH-12-1-0406
- antitumor agents;
- drug design;
Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.